Blog

Conducts 27% Workforce Reduction, Ceases Operations at Applied DNA Clinical Labs, Positions LineaRx for Growth STONY BROOK, N.Y. – June 30, 2025 – Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in PCR-based DNA technologies, announced a strategic restructuring and realignment of resources to focus exclusively on its synthetic DNA manufacturing business, LineaRx. As part of actions undertaken, the Company implemented […]

Pivot to U.S.-based Supply Chain for Critical Input Materials Completed STONY BROOK, N.Y. April 21, 2025 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in PCR-based DNA technologies, today announced that LineaRx, Inc., the Company’s majority-owned subsidiary, has completed a long-term initiative to source critical input materials for its […]

LineaRx, an Applied DNA company, will showcase its Linea™ IVT and Linea™ DNA platforms at the upcoming DNA Process Development & Manufacturing Summit, in Boston, MA. March 26-27, 2025 Team members will be available during the show for one-on-one meetings. Email info@adnas.com to schedule a meeting today!

LineaRx, an Applied DNA company, will showcase its Linea™ IVT and Linea™ DNA platforms at the upcoming World Vaccine Congress, to be held April 21 – 24, 2025 at the Walter E. Washington Convention Center in Washington, D.C. We are exhibiting at Booth 479. Team members will be available during the show for one-on-one meetings. Email […]

AUTHORS Atsuko Sangria, PhD, Director, Drug Substance Process Development, Kudo Biotechnology Aaron Chung, Director, Nucleic Acid Platforms, LineaRx/Applied DNA SciencesYuhua Sun, Executive Director of R&D, LineaRx/Applied DNA Sciences Overview mRNA therapeutics offer benefits far beyond pandemic vaccines, including cancer vaccines, protein replacement, and cell and gene therapies. Swift development and delivery are crucial, as delays […]

Realizing the full clinical potential of circular and self-amplifying RNAs across infectious diseases, CAR-T therapy, gene therapy and beyond with improved efficacy, functionality and immunogenicity. May 28 – 29, 2025 • Boston, MA

Signals Start of New Commercialization Phase for LineaRx SubsidiaryCompany Negotiating GMP Supply AgreementCompany Reaffirms Strategic Restructuring Timeline STONY BROOK, N.Y., January 10, 2025 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the “facility”) […]

Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies STONY BROOK, N.Y., December 18, 2024 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic […]